Open AccessImatinib as a Treatment Option for Systemic Non-Langerhans Cell Histiocytoses
Author(s) -
Jochen Utikal,
Selma Ugurel,
Hjalmar Kurzen,
Philipp Erben,
Andreas Reiter,
Andreas Hochhaus,
Thomas Nebe,
Ralf Hildenbrand,
Uwe Haberkorn,
Sergij Goerdt,
Dirk Schadendorf
Publication year - 2007
Publication title -
archives of dermatology
Language(s) - English
Resource type - Journals
eISSN - 1538-3652
pISSN - 0003-987X
DOI - 10.1001/archderm.143.6.736
Subject(s) - histiocyte , medicine , imatinib , histiocytosis , erdheim–chester disease , bone marrow , langerhans cell , pathology , imatinib mesylate , langerhans cell histiocytosis , disease , immunology , antigen , myeloid leukemia
Systemic non-Langerhans cell histiocytoses are disorders characterized by the accumulation of histiocytes that do not meet the criteria for Langerhans cells in various organs. So far, no causative treatment is known.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom